{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:23Z","timestamp":1761093143529,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.urolonc.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T01:38:27Z","timestamp":1661650707000},"page":"538.e15-538.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-4209","authenticated-orcid":false,"given":"Kyriaki","family":"Papadopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia-Angeliki","family":"Koliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tsimiliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Kotoula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Periklis","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Goussia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinos","family":"Tsiatas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Visvikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos","family":"Chatzopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Nifora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Charchanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Koumarianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Psyrri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florentia","family":"Fostira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epaminontas","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","article-title":"Molecular markers in bladder cancer","volume":"37","author":"Soria","year":"2019","journal-title":"World J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.07.007_bib0002","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.3390\/ijms19092777","article-title":"Biomarkers for predicting clinical outcomes of chemoradiation-based bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Koga","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2022.07.007_bib0003","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder cancer in the genomic era","volume":"143","author":"Guo","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"17","key":"10.1016\/j.urolonc.2022.07.007_bib0004","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.3390\/ijms21176271","article-title":"Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going?","volume":"21","author":"Pardo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0006","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0007","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0008","first-page":"1","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2022.07.007_bib0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.urolonc.2022.07.007_bib0010","doi-asserted-by":"crossref","first-page":"e2587","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clinics"},{"issue":"12","key":"10.1016\/j.urolonc.2022.07.007_bib0011","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3233\/BLC-170129","article-title":"Molecular and clinical insights into the role and significance of mutated dna repair genes in bladder cancer","volume":"4","author":"Abbosh","year":"2018","journal-title":"Bladder Cancer"},{"issue":"14","key":"10.1016\/j.urolonc.2022.07.007_bib0013","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.urolonc.2022.07.007_bib0014","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2022.07.007_bib0015","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.07.007_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/jclinpath-2019-206256","article-title":"Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder","volume":"73","author":"Hodgson","year":"2020","journal-title":"J Clin Pathol"},{"issue":"11","key":"10.1016\/j.urolonc.2022.07.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1644108","article-title":"Clinical impact of T cells, B cells and the PD-1\/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens","volume":"8","author":"Wahlin","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2018.11.016","article-title":"Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: deep sequencing data from ovarian cancer patients","volume":"152","author":"Kotoula","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating discovery of functional mutant alleles in cancer","volume":"8","author":"Chang","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death & Differentiation"},{"issue":"11","key":"10.1016\/j.urolonc.2022.07.007_bib0022","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrg2663","article-title":"Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity","volume":"10","author":"Cleaver","year":"2009","journal-title":"Nat Rev Genet"},{"issue":"10","key":"10.1016\/j.urolonc.2022.07.007_bib0023","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0024","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7492","key":"10.1016\/j.urolonc.2022.07.007_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Network","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.urolonc.2022.07.007_bib0026","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2018.05.49","article-title":"Emerging biomarkers and targeted therapies in urothelial carcinoma","volume":"6","author":"Mendiratta","year":"2018","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0027","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.urolonc.2022.07.007_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11934-018-0853-5","article-title":"Molecular characterization of bladder cancer","volume":"19","author":"Chandrasekar","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.urolonc.2022.07.007_bib0029","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.urolonc.2007.07.011","article-title":"Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: A long-term study","volume":"26","author":"Salinas-S\u00e1nchez","year":"2008","journal-title":"Urol Oncol"},{"issue":"34","key":"10.1016\/j.urolonc.2022.07.007_bib0030","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2006.10.4125","article-title":"p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer","volume":"25","author":"George","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0031","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2022.07.007_bib0032","doi-asserted-by":"crossref","first-page":"530.e7","DOI":"10.1016\/j.urolonc.2018.05.025","article-title":"The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer","volume":"36","author":"Aljabery","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.07.007_bib0033","doi-asserted-by":"crossref","first-page":"e8261","DOI":"10.7717\/peerj.8261","article-title":"Significance of TP53 mutation in bladder cancer disease progression and drug selection","volume":"7","author":"Wu","year":"2019","journal-title":"PeerJ"},{"issue":"25","key":"10.1016\/j.urolonc.2022.07.007_bib0034","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status","volume":"29","author":"Stadler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2022.07.007_bib0036","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ng.2800","article-title":"Frequent truncating mutations of STAG2 in bladder cancer","volume":"45","author":"Solomon","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0037","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.18632\/aging.102728","article-title":"EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients","volume":"12","author":"Zhu","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.urolonc.2022.07.007_bib0038","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.21037\/tau.2017.09.18","article-title":"Young Academic Urologist Urothelial Carcinoma Group of the European Association of U. Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?","volume":"6","author":"Wezel","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.007_bib0039","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/CBM-182379","article-title":"Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder","volume":"25","author":"Kuang","year":"2019","journal-title":"Cancer Biomarkers"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.urolonc.2022.07.007_bib0041","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-0330","article-title":"Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer","volume":"20","author":"Nickerson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.urolonc.2022.07.007_bib0042","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1158\/1078-0432.CCR-14-0257","article-title":"Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival","volume":"20","author":"Yap","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2022.07.007_bib0043","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.07.007_bib0044","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1634\/theoncologist.2019-0851","article-title":"Prognostic value of DNA damage response genomic alterations in relapsed\/advanced urothelial cancer","volume":"25","author":"Yin","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.urolonc.2022.07.007_bib0045","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.urolonc.2019.12.012","article-title":"MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass","volume":"38","author":"Fraune","year":"2020","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.07.007_bib0046","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.urolonc.2022.07.007_bib0047","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0048","first-page":"1","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.urolonc.2022.07.007_bib0049","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0051","first-page":"1","article-title":"Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy","volume":"8","author":"Huang","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.urolonc.2022.07.007_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205746","article-title":"Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2022.07.007_bib0053","doi-asserted-by":"crossref","first-page":"e3921","DOI":"10.7717\/peerj.3921","article-title":"Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ-and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy","volume":"5","author":"Zhang","year":"2017","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0054","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.21037\/tau.2019.04.02","article-title":"Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma","volume":"8","author":"Kim","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.07.007_bib0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/BLC-160067","article-title":"The role of PD-L1 expression and intratumoral lymphocytes in response to perioperative chemotherapy for urothelial carcinoma","volume":"2","author":"Erlmeier","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2022.07.007_bib0056","first-page":"8375348","article-title":"Predictive and prognostic role of pd-l1 in urothelial carcinoma patients with Anti-PD-1\/PD-L1 therapy: a systematic review and meta-analysis","author":"Liu","year":"2020","journal-title":"Dis Markers"},{"issue":"21","key":"10.1016\/j.urolonc.2022.07.007_bib0057","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.3390\/cancers13215500","article-title":"Molecular classification of bladder urothelial carcinoma using NanoString-based gene expression analysis","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.007_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","volume":"7","author":"Vidotto","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2022.07.007_bib0059","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2022.07.007_bib0060","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/cancers12071784","article-title":"Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy","volume":"12","author":"Font","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.007_bib0061","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/icu.20200425","article-title":"Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer","volume":"62","author":"Razzaghdoust","year":"2021","journal-title":"Investigative and clinical urology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:37Z","timestamp":1761042397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922002666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1078143922002666"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.07.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}